<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Mol Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Molecular psychiatry</journal-title></journal-title-group><issn pub-type="ppub">1359-4184</issn><issn pub-type="epub">1476-5578</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8026116</article-id><article-id pub-id-type="pmcid-ver">PMC8026116.1</article-id><article-id pub-id-type="pmcaid">8026116</article-id><article-id pub-id-type="pmcaiid">8026116</article-id><article-id pub-id-type="manuscript-id">NIHMS1687837</article-id><article-id pub-id-type="pmid">25707397</article-id><article-id pub-id-type="doi">10.1038/mp.2015.1</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1687837</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1687837</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">In-vivo</italic> imaging of grey and white matter neuroinflammation in Alzheimer&#8217;s disease: a positron emission tomography study with a novel radioligand, [<sup>18</sup>F]-FEPPA</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Suridjan</surname><given-names initials="I">I</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pollock</surname><given-names initials="BG">BG</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Verhoeff</surname><given-names initials="N">NPLG</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Voineskos</surname><given-names initials="AN">AN</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chow</surname><given-names initials="T">T</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rusjan</surname><given-names initials="PM">PM</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lobaugh</surname><given-names initials="NJ">NJ</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Houle</surname><given-names initials="S">S</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mulsant</surname><given-names initials="BH">BH</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mizrahi</surname><given-names initials="R">R</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A4">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada;</aff><aff id="A2"><label>2</label>Institute of Medical Science, University of Toronto, Toronto, ON, Canada;</aff><aff id="A3"><label>3</label>Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, ON, Canada;</aff><aff id="A4"><label>4</label>Department of Psychiatry, University of Toronto, Toronto, ON, Canada;</aff><aff id="A5"><label>5</label>Centre for Mental Health, Baycrest Health Sciences, Toronto, ON, Canada</aff><aff id="A6"><label>6</label>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</aff><author-notes><corresp id="CR1">Correspondence: Dr R Mizrahi, Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), 250 College St, Toronto, ON M5T 1R8, Canada. <email>romina.mizrahi@camhpet.ca</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P34">CONFLICT OF INTEREST</p><p id="P35">The authors declare no conflict of interest</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><volume>20</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">379070</issue-id><fpage>1579</fpage><lpage>1587</lpage><pub-history><event event-type="nihms-submitted"><date><day>29</day><month>03</month><year>2021</year></date></event><event event-type="pmc-release"><date><day>07</day><month>04</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>07</day><month>04</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-27 17:25:36.867"><day>27</day><month>04</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1687837.pdf"/><abstract id="ABS1"><p id="P1">Our primary aim was to compare neuroinflammation in cognitively intact control subjects and patients with Alzheimer&#8217;s disease (AD) by using positron emission tomography (PET) with translocator protein 18kDa (TSPO)-specific radioligand [<sup>18</sup>F]-FEPPA. [<sup>18</sup>F]-FEPPA PET scans were acquired on a high-resolution research tomograph in 21 patients with AD (47&#8211; 81 years) and 21 control subjects (49&#8211;82 years). They were analyzed by using a 2-tissue compartment model with arterial plasma input function. Differences in neuroinflammation, indexed as [<sup>18</sup>F]-FEPPA binding were compared, adjusting for differences in binding affinity class as determined by a single polymorphism in the TSPO gene (rs6971). In grey matter areas, [<sup>18</sup>F]-FEPPA was significantly higher in AD compared with healthy control subjects. Large increases were seen in the hippocampus, prefrontal, temporal, parietal and occipital cortex (average Cohen&#8217;s <italic toggle="yes">d</italic> = 0.89). Voxel-based analyses confirmed significant clusters of neuroinflammation in the frontal, temporal and parietal cortex in patients with AD. In white matter, [<sup>18</sup>F]-FEPPA binding was elevated in the posterior limb of the internal capsule, and the cingulum bundle. Higher neuroinflammation in the parietal cortex (<italic toggle="yes">r</italic> = &#8722; 0.7, <italic toggle="yes">P</italic> = 0.005), and posterior limb of the internal capsule (<italic toggle="yes">r</italic> = &#8722; 0.8, <italic toggle="yes">P</italic> = 0.001) was associated with poorer visuospatial function. In addition, a higher [<sup>18</sup>F]-FEPPA binding in the posterior limb of the internal capsule was associated with a greater impairment in language ability (<italic toggle="yes">r</italic> = &#8722; 0.7, <italic toggle="yes">P</italic> = 0.004). Elevated neuroinflammation can be detected in AD patients throughout the brain grey and white matter by using [<sup>18</sup>F]-FEPPA PET. Our results also suggest that neuroinflammation is associated with some cognitive deficits.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>